demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
anti-inflammatory therapies
colchicine COLCHIVID
stem cells Shi Shu
vilobelimab (IFX-1) PANAMO

1 studies excluded by filtering options 1

9868 Brunetti, 2020 1110not a RCTrisk of bias not avaialble